Relation between intracellular accumulation and cytotoxic activity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N′)bis(myristato)]platinum(II) suspended in lipiodol

Biological and Pharmaceutical Bulletin

Volumn 26, Issue 5, 2003, Pages 683-686

  Kishimoto, Shuichi ^a   Ohtani, Aya ^a   Fukuda, Hisayuki ^a   Fukushima, Shoji ^a   Takeuchi, Yoshikazu ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

Author keywords

Lipiodol; Platinum; SM 11355,cisplatin (CDDP)

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DNA; IODINATED POPPYSEED OIL; METHIONINE; PLATINUM DERIVATIVE; REAGENT; SM 11355; UNCLASSIFIED DRUG; [(1,2 CYCLOHEXANEDIAMINE N,N')BIS(MYRISTATO)]PLATINUM; DRUG CARRIER; PLATINUM COMPLEX;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOACCUMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DNA ADDUCT; DRUG ACCUMULATION; DRUG FORMULATION; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SPACE; NONHUMAN; RAT; TUMOR CELL LINE; TUMOR MODEL; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG INTERACTION; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA ADDUCTS; DRUG CARRIERS; DRUG INTERACTIONS; IODIZED OIL; METHIONINE; ORGANOPLATINUM COMPOUNDS; RATS;

EID: 1542754755     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.26.683     Document Type: Article

References (18)

1. Kishimoto S , Fukui M., Fukushima S., Nakano M , Reg. Cancer Treat., 1-2, 25-29 (1992)
2. Ono Y., Yoshioka H., Ohkusa A , Okafuji T., Kawakami A., Ishida O., Suzuki T., Fukui M , J Jpn Soc Cancer Ther., 27, 49-58 (1992)
3. Kishimoto S., Miyazawa K., Terakawa Y., Ashikari H., Ohtani A., Fukushima S , Takeuchi Y., Jpn. J Cancer Res., 91, 1326-1332 (2000).
4. Kishimoto S., Miyazawa K., Fukushima S., Takeuchi Y., Jpn. J Cancer Res., 91, 99-104 (2000)
5. Han I., Ling Y. H., al-Baker S., Khokhar A. R., Perez-Soler R., Cancer Res., 53, 4913-4919 (1993)
6. Cooley M E., Davis L. E , DeStefano M., Abrahm J., Cancer Nurs., 17, 173-184 (1994).
7. Daley-Yates P. T., McBrien D. C., Biochem. Pharmacol., 33, 3063-3070 (1984).
8. Farris F. F., King F G., Dedrick R. L., Litterst C L , J. Pharmacokinet Biopharm., 13, 13-39 (1985)
9. Kroning R., Lichtenstein A. K., Nagami G. T., Cancer Chemother. Pharmacol., 45, 43-49 (2000).
10. Boisdron-Celle M., Lebouil A , Allain P., Gamelin E., Bull. Cancer, 88, S14-S19 (2001).
11. Mauldin S. K., Plescia M , Richard F. A , Wyrick S. D , Voyksner R D., Chancy S. G , Biochem. Pharmacol., 37, 3321-3333 (1988).
12. Chaney S. G., Wyrick S., Till G. K , Cancer Res., 50, 4539-4545 (1990).
13. Heudi O , Mercier-Jobard S., Cailleux A., Allain P., Biopharm. Drug Dispos., 20, 107-116 (1999).
14. Araki H , Fukushima M., Kamiyama Y., Shirasaka T., Cancer Lett , 160, 185-191 (2000).
15. Goel R., Cleary S. M., Horton C., Kirmani S., Abramson I., Kelly C., Howell S. B., J. Natl Cancer Inst , 81, 1552-1560 (1989).
16. Kishimoto S., Noguchi T., Yamaoka T , Fukushima S , Takeuchi Y , Biol Pharm Bull , 23, 487-491 (2000).
17. Kishimoto S., Noguchi T., Yamaoka T., Fukushima S., Takeuchi Y., Biol Pharm Bull , 23, 637-640 (2000).
18. Ekborn A , Laurell G., Johnstrom P., Wallin I., Eksborg S , Ehrsson H., Hear Res , 165, 53-61 (2002)